Candel Therapeutics (CADL) Net Income towards Common Stockholders (2020 - 2025)
Candel Therapeutics (CADL) posted Net Income towards Common Stockholders of -$15.2 million for Q4 2025, up 35.61% sequentially from -$23.6 million in Q3 2025, and down 79.58% YoY from -$74.6 million in Q4 2024.
Candel Therapeutics (CADL) Net Income towards Common Stockholders (2020 - 2025) Analysis & Trends
Candel Therapeutics has reported Net Income towards Common Stockholders for 6 years, with the latest figure at -$15.2 million in Q4 2025.
- Quarterly Net Income towards Common Stockholders fell 79.58% year-over-year to -$15.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$81.4 million (down 14.32% YoY) and the FY2025 annual result came in at -$109.6 million, down 83.05% from the prior year.
- Net Income towards Common Stockholders rose to -$15.2 million in Q4 2025 per CADL's latest filing, from -$23.6 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at -$4.7 million in Q1 2021 and troughed at -$38.2 million in Q1 2022.
- A 5-year average of -$15.6 million and a median of -$10.2 million in 2023 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2022 and 2023: Net Income towards Common Stockholders slumped 717.13% in 2022, then soared 73.19% in 2023.
- Over 5 years, Net Income towards Common Stockholders stood at -$26.1 million in 2021, then soared by 65.62% to -$9.0 million in 2022, then decreased by 12.96% to -$10.1 million in 2023, then climbed by 16.29% to -$8.5 million in 2024, then tumbled by 79.58% to -$15.2 million in 2025.
- According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$15.2 million, -$23.6 million, and -$21.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Candel Therapeutics | 643.41 Mn | 643.41 Mn | - | -15.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -15.23 Mn |
| Sep 30, 2025 | -23.65 Mn |
| Jun 30, 2025 | -21.52 Mn |
| Mar 31, 2025 | -21.05 Mn |
| Dec 31, 2024 | -8.48 Mn |
| Sep 30, 2024 | -28.82 Mn |
| Jun 30, 2024 | -25.72 Mn |
| Mar 31, 2024 | -8.23 Mn |
| Dec 31, 2023 | -10.13 Mn |
| Sep 30, 2023 | -9.52 Mn |
| Jun 30, 2023 | -19.57 Mn |
| Mar 31, 2023 | -10.23 Mn |
| Dec 31, 2022 | -8.97 Mn |
| Sep 30, 2022 | -9.06 Mn |
| Jun 30, 2022 | -9.12 Mn |
| Mar 31, 2022 | -38.15 Mn |
| Dec 31, 2021 | -26.08 Mn |
| Sep 30, 2021 | -7.90 Mn |
| Jun 30, 2021 | -5.32 Mn |
| Mar 31, 2021 | -4.67 Mn |